dalteparin has been researched along with Cognition Disorders in 5 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Ardes, D | 1 |
| Carrarini, C | 1 |
| Russo, M | 1 |
| Dono, F | 1 |
| Speranza, R | 1 |
| Digiovanni, A | 1 |
| Martinotti, G | 1 |
| Di Iorio, A | 1 |
| Onofrj, M | 1 |
| Cipollone, F | 1 |
| Bonanni, L | 1 |
| Feldinger, LE | 1 |
| Timmer, NM | 1 |
| van Dijk, L | 1 |
| van der Zee, CE | 1 |
| Kiliaan, A | 1 |
| de Waal, RM | 1 |
| Verbeek, MM | 1 |
| Wahl, F | 2 |
| Grosjean-Piot, O | 2 |
| Bareyre, F | 1 |
| Uzan, A | 2 |
| Stutzmann, JM | 2 |
| Mary, V | 1 |
| Pratt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine[NCT04507178] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-02-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Cognition Disorders
| Article | Year |
|---|---|
Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review.
Topics: Animals; Anticoagulants; Brain Edema; Brain Injuries; Brain Ischemia; Cognition Disorders; Enoxapari | 2002 |
4 other studies available for dalteparin and Cognition Disorders
| Article | Year |
|---|---|
Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization.
Topics: Aged; Aged, 80 and over; Anticoagulants; C-Reactive Protein; Cognition Disorders; Cohort Studies; Co | 2021 |
Recurrent and consistent improvement of cognitive impairment and depression after short time of treatment with enoxaparin.
Topics: Accidental Falls; Aged, 80 and over; Anticoagulants; Cognition Disorders; Depression; Enoxaparin; Hi | 2013 |
Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition Disorders; Disease Models, Animal; Enox | 2010 |
Enoxaparin reduces brain edema, cerebral lesions, and improves motor and cognitive impairments induced by a traumatic brain injury in rats.
Topics: Animals; Anticoagulants; Body Water; Brain; Brain Edema; Brain Injuries; Cognition; Cognition Disord | 2000 |